Omada Health is a virtual healthcare company that helps people manage chronic conditions like diabetes and obesity through digital coaching and connected devices. The company has reached significant scale, reporting $78 million in revenue for the first quarter of 2026, a 42% increase from the prior year. With over 1.02 million total members, Omada is now a primary clinical partner for large employers and the nation’s three largest pharmacy benefit managers.
The investment thesis on Omada Health is that it has built the essential digital clinical layer for the GLP-1 weight-loss era, using its deep distribution with pharmacy benefit managers to lock out competitors. While many companies sell weight-loss drugs, Omada provides the lifestyle coaching and data tracking that insurers and employers require to justify the high cost of those medications.
We think Omada Health has successfully transitioned from a standalone wellness app into a necessary piece of the national healthcare infrastructure. The combination of million-member scale and partnerships with the gatekeepers of US healthcare makes its position difficult to replicate.
What does it do?
Omada Health is a growth-stage business that earns money by charging employers and health plans a recurring fee for managing the chronic health conditions of their members. The company provides "virtual-first" care, meaning patients use a mobile app to connect with human health coaches and use cellular-connected devices like scales or glucose monitors that send data directly to Omada. Money flows primarily through per-member-per-month fees or performance-based payments where Omada is paid more if it helps a patient lose weight or lower their blood sugar. Customers like large corporations pay for this because it reduces their overall medical claims and pharmacy spending over time.
Where does revenue come from?
Almost all of Omada's revenue comes from service fees paid by large employers, health insurance plans, and pharmacy benefit managers (PBMs). Revenue is concentrated in the United States, as the business model is built specifically around the American private insurance system. The company does not sell directly to individual consumers, instead relying on its partners to "enroll" their employees or members into the program.
Revenue Breakdown
Who are its customers?
Omada Health serves over 1.02 million total members across 2,000 different organizations, including some of the largest employers and health plans in the country. The company has a massive distribution advantage because it is now integrated into all three of the nation’s leading pharmacy benefit managers: CVS Caremark, Express Scripts, and most recently, Optum Rx. This gives Omada access to a vast majority of commercially insured lives in the U.S. In the first quarter of 2026, the member base grew 51% compared to the previous year, showing that these large-scale partnerships are accelerating enrollment.
What gives it staying power?
Omada has staying power because it is deeply embedded in the complex technical and clinical workflows of its PBM and insurance partners. Once a health plan integrates Omada’s data into its billing and clinical systems, the switching costs become very high. Furthermore, its 15 years of clinical data create a significant barrier for newer competitors.
Where is it headed?
Omada is pivoting toward becoming the primary clinical "companion" for patients taking GLP-1 weight-loss medications. Management is betting that by providing the lifestyle support and muscle-mass tracking that these drugs require, Omada can capture a larger share of the massive spending shifting toward anti-obesity medications. This includes a new direct-to-employer partnership with Eli Lilly.
The business is rapidly accelerating as it hits the one-million-member milestone. Revenue grew 42% year-over-year in the first quarter of 2026 to $78 million, and management raised full-year guidance to a midpoint of $326 million. This acceleration is driven by deeper penetration into the pharmacy benefit manager (PBM) channel, which allows for faster member onboarding than traditional sales.
Cash quality is improving significantly as the company approaches a break-even point. Omada reported its first positive Adjusted EBITDA of $1 million in Q1 2026, a sharp improvement from a $4 million loss the year before. While the business is still technically losing a small amount of money on a GAAP basis, the narrowing net loss of $3 million suggests that current cash of $212 million is more than enough to reach self-sustainability.
Omada maintains a highly resilient balance sheet with zero debt and a substantial cash pile. The company ended the most recent quarter with $211.8 million in cash and cash equivalents, which is high for a business that is now generating positive Adjusted EBITDA. This clean balance sheet provides a massive safety net and allows the company to invest in new programs like the GLP-1 Care Track without needing to raise more capital.
Omada Health has successfully reached the scale where its high gross margins are beginning to fund the entire business.
Gross margins reached 62% in the most recent quarter, proving that Omada can scale its member base without a proportional increase in costs. This expansion from 58% a year ago shows that its AI-enabled coaching and automated data tracking are making its human health coaches more efficient.
Member growth at 51% is currently faster than revenue growth at 42%, which could signal lower revenue per member in newer segments. If the new GLP-1 partnerships carry lower fees or take longer to bill, it could pressure the timeline for reaching full GAAP profitability.
Reached 1M members and Adjusted EBITDA profitability ahead of internal targets.
Managed cash to $212M without further dilution since the IPO.
Sean Duffy is a co-founder with a significant long-term equity stake.
Capital Allocation Track Record
Sean Duffy has demonstrated exceptional strategic judgment by pivoting Omada from a simple diabetes prevention app into a diversified clinical platform integrated with the PBM giants. Under his leadership, the company has hit its growth targets while simultaneously improving margins, a difficult balance in the virtual health space. The decision to embrace the GLP-1 trend early as a clinical support layer, rather than just a drug prescriber, appears to be a major win that distinguishes Omada from more promotional competitors.
The primary governance risk is the company’s heavy reliance on Duffy’s vision and his relationships with PBM executives. While there is a deep bench of experienced leaders, including a veteran CTO and Chief People Officer, the "founder-led" nature of the company is a core part of its identity. However, with zero debt and a proven ability to raise capital on good terms, the financial risks usually associated with high-growth virtual health companies are lower here.
Omada Health is projected to hit its first full year of positive EPS in FY2026, driven by the massive scale of its one-million-member base and the high margins of its new GLP-1 Care Track. The forecast assumes a 25% revenue CAGR as Omada deepens its penetration into the "Big Three" PBMs. As the business scales, operating margins are expected to expand from the low single digits to the mid-teens, turning it into a high-margin clinical software business.
GLP-1 Care Track becomes the industry standard for support. If Omada becomes the default support platform for GLP-1 drugs, it could triple its revenue per member.
PBM integrations drive automatic enrollment at near-zero cost. Deep PBM ties allow Omada to add millions of members with almost no additional marketing spending.
International expansion through global employer health plans. Omada has a clear path to follow its multinational customers into international markets, expanding its addressable market.
PBMs build their own in-house digital coaching platforms. If Optum or CVS decide to build their own clinical coaching, they could remove Omada from their preferred lists.
GLP-1 drug costs become so high that employers cut coverage. A mass retreat from weight-loss drug coverage by employers would destroy the demand for Omada's companion support.
Data breach exposes sensitive member medical information. As a healthcare company, a single major security failure could destroy the trust of its PBM and insurance partners.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use an EV/Revenue framework (Enterprise Value to Revenue) with an explicit bridge to profitability. This fits Omada because the company is in a high-growth scale-up phase where revenue growth and gross margin expansion are the most reliable indicators of future cash flow, especially as it approaches its first full year of Adjusted EBITDA profitability.
Applying a 4.7x multiple to our FY2026 revenue estimate of $326 million, plus $212 million in net cash, results in a fair value of $29 per share. A 4.7x multiple sits at the higher end of the healthcare IT peer range (LifeStance 3.0x, GoodRx 4.2x) because Omada’s 42% YoY growth significantly outpaces the industry average. We divide the resulting $1.74 billion equity value by 59.4 million diluted shares to reach the $29 target.
Cross-checked with a Forward P/E approach using FY2028 consensus EPS of $0.76 multiplied by a 35x peer growth multiple, we get a value of $26.60. When discounted back to 2026 at a 10% rate, this supports a present fair value of approximately $22 to $24. This is within 17% of our primary $29 answer, which is a reasonable disagreement given that our primary model captures the immediate upside from the raised FY2026 revenue guidance and GLP-1 catalyst that may not yet be fully reflected in 2028 consensus EPS.
We're assuming the GLP-1 Flex Care program drives at least 30% of new enrollment growth through 2027. The program was launched in March 2026 to help employers manage the high cost of weight-loss drugs, and early traction in Q1 suggests it is becoming a primary door for new multi-condition members.
We're assuming Omada reaches a 15% Adjusted EBITDA margin by FY2028. Adjusted EBITDA (earnings before interest, taxes, and non-cash items) turned positive in Q1 2026, and management's raised guidance for the full year suggests that scaling the platform across 1.02 million members is finally yielding significant operating leverage.
We're assuming member retention remains stable above 85% as the platform expands. The value of the data moat depends on long-term tracking of patient outcomes; any significant churn in the "multi-condition" cohorts would undermine the premium multiple Omada currently commands over simpler healthcare IT services.
The biggest risk is that Pharmacy Benefit Managers (PBMs) launch competing internal coaching tools, cutting Omada out of the high-value GLP-1 clinical management layer. This would likely force the EV/Revenue multiple to compress from 4.7x to 2.5x, knocking roughly $12 off the per-share fair value. Watch for PBM "in-housing" announcements or changes in referral patterns from major insurers.
Bear case ($18): Revenue growth for the Service segment drops below 20% as PBMs launch competing internal coaching tools; or Adjusted EBITDA margins fail to reach the 10% milestone by FY2027 due to rising member acquisition costs.
Bull case ($38): GLP-1 Flex Care adoption exceeds 40% of the employer customer base by the end of FY2026; or The company achieves GAAP net profitability two quarters ahead of consensus estimates (H1 2027).
Clearthesis wrote this report from 38 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 26, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.